AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 1309127 — intervention group
Group type: COMPARATOR
Intervention: Assisted hatching by zona drilling using acidic Tyrode's solution on embryos with thin zonae (< 13 microns).
Number of subjects: 330
Study 1309127 — intervention group
Group type: COMPARATOR
Intervention: Control group with embryos having thin zonae left intact.
Number of subjects: 330
Study 1309127 — intervention group
Group type: EXPERIMENTAL
Intervention: Assisted hatching with removal of small amounts of fragments from embryos during assisted hatching.
Number of subjects: 330
Study 6532286 — intervention group
Group type: EXPERIMENTAL
Intervention: 1% indomethacin ophthalmic solution
Number of subjects: 106
Study 6532286 — intervention group
Group type: COMPARATOR
Intervention: Routine preoperative dilating drops (Control)
Number of subjects: 106
Study 6532286 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 106
Study 30316548 — intervention group
Group type: EXPERIMENTAL
Intervention: Eight-week pulmonary rehabilitation program (home or hospital)
Number of subjects: 166
Study 29443739 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulmonary rehabilitation
Number of subjects: 60
Study 29443739 — intervention group
Group type: COMPARATOR
Intervention: Control group (healthy volunteers)
Number of subjects: 60
Study 26963847 — intervention group
Group type: EXPERIMENTAL
Intervention: Tailored activity pacing
Number of subjects: 193
Study 26963847 — intervention group
Group type: EXPERIMENTAL
Intervention: General activity pacing
Number of subjects: 193
Study 26963847 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 193
Study 25107318 — intervention group
Group type: EXPERIMENTAL
Intervention: Problem Solving Therapy‐Primary Care (PST‐PC)
Number of subjects: 60
Study 25107318 — intervention group
Group type: COMPARATOR
Intervention: Dietary Education (DIET)
Number of subjects: 60
Study 25107318 — intervention group
Group type: EXPERIMENTAL
Intervention: PST‐PC
Number of subjects: 60
Study 25107318 — intervention group
Group type: COMPARATOR
Intervention: DIET
Number of subjects: 60
Study 22644259 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental group (EG) using EORTC QLQ‐C30 + LC13 questionnaire via digital table interface
Number of subjects: 171
Study 22644259 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental group (EG)
Number of subjects: 171
Study 22644259 — intervention group
Group type: COMPARATOR
Intervention: Control group (CG) using paper version of EORTC QLQ‐C30 + LC13 questionnaire
Number of subjects: 171
Study 21392377 — intervention group
Group type: EXPERIMENTAL
Intervention: Five years of OPUS treatment
Number of subjects: 400
Study 21392377 — intervention group
Group type: COMPARATOR
Intervention: Two years of OPUS treatment
Number of subjects: 400
Study 21392377 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment
Number of subjects: 400
Study 19255201 — intervention group
Group type: EXPERIMENTAL
Intervention: Circular external fixation
Number of subjects: 82
Study 19255201 — intervention group
Group type: COMPARATOR
Intervention: Open reduction and internal fixation
Number of subjects: 82
Study 19255201 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 82
Study 16969747 — intervention group
Group type: EXPERIMENTAL
Intervention: Polymethylmethacrylate (PMMA)
Number of subjects: 107
Study 16969747 — intervention group
Group type: COMPARATOR
Intervention: Titanium cage
Number of subjects: 107
Study 15088880 — intervention group
Group type: EXPERIMENTAL
Intervention: Coronally positioned flap + subepithelial connective tissue graft (CPF + SCTG)
Number of subjects: 11
Study 15088880 — intervention group
Group type: COMPARATOR
Intervention: Coronally positioned flap alone (CPF)
Number of subjects: 11
Study 11248153 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard chemotherapy plus trastuzumab
Number of subjects: 469
Study 11248153 — intervention group
Group type: EXPERIMENTAL
Intervention: Anthracycline and cyclophosphamide plus trastuzumab
Number of subjects: 469
Study 11248153 — intervention group
Group type: COMPARATOR
Intervention: Anthracycline and cyclophosphamide alone
Number of subjects: 469
Study 11248153 — intervention group
Group type: EXPERIMENTAL
Intervention: Paclitaxel plus trastuzumab
Number of subjects: 469
Study 11248153 — intervention group
Group type: COMPARATOR
Intervention: Paclitaxel alone
Number of subjects: 469
Study 9579879 — intervention group
Group type: EXPERIMENTAL
Intervention: rhEPO (5x500 U/kg body weight) + oral Fe2+ (300 mg/day)
Number of subjects: 76
Study 9579879 — intervention group
Group type: COMPARATOR
Intervention: Placebo + oral Fe2+ (300 mg/day)
Number of subjects: 76
Study 7538400 — intervention group
Group type: EXPERIMENTAL
Intervention: Prolase II fiber (cytocare) treatment for BPH
Number of subjects: 15
Study 7538400 — intervention group
Group type: COMPARATOR
Intervention: TURP (Transurethral Resection of the Prostate)
Number of subjects: 15
Study 2406326 — intervention group
Group type: EXPERIMENTAL
Intervention: Eicosapentaenoic acid (EPA) 3.5 gm/day for 8 weeks
Number of subjects: 7
Study 2406326 — intervention group
Group type: COMPARATOR
Intervention: Diluent alone (control)
Number of subjects: 7
Study 6797732 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitroglycerin (NTG) ointment, 7.5 mg
Number of subjects: 21
Study 6797732 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol (P), 20-40 mg, 3 times daily
Number of subjects: 21
Study 6797732 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine (N), 10 mg, 3-4 times daily
Number of subjects: 21
Study 31870556 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of pimasertib (60 mg daily) + SAR245409 (70 mg daily)
Number of subjects: 65
Study 31870556 — intervention group
Group type: COMPARATOR
Intervention: Pimasertib alone (60 mg BID)
Number of subjects: 65
Study 31870556 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of pimasertib + SAR245409
Number of subjects: 65
Study 31487422 — intervention group
Group type: EXPERIMENTAL
Intervention: GA plus endoscopic SPGB
Number of subjects: 60
Study 31487422 — intervention group
Group type: COMPARATOR
Intervention: GA alone (control)
Number of subjects: 60
Study 28891320 — intervention group
Group type: EXPERIMENTAL
Intervention: Nephrostomy tube (Group 1)
Number of subjects: 90
Study 28891320 — intervention group
Group type: EXPERIMENTAL
Intervention: Double‐J (JJ) stent (Group 2)
Number of subjects: 90
Study 28891320 — intervention group
Group type: EXPERIMENTAL
Intervention: Open‐ended ureteral catheter (Group 3)
Number of subjects: 90
Study 26242218 — intervention group
Group type: EXPERIMENTAL
Intervention: Habit-based intervention to reduce sedentary behaviour
Number of subjects: 23
Study 24095610 — intervention group
Group type: EXPERIMENTAL
Intervention: Taxane-based regimen
Number of subjects: 153
Study 24095610 — intervention group
Group type: EXPERIMENTAL
Intervention: Taxane-based regimen with clinical variables
Number of subjects: 153
Study 21298288 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy combined with Chinese herbal medicine (Kangliuzengxiao decoction during chemotherapy and Feiyanning decoction after chemotherapy)
Number of subjects: 121
Study 21298288 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy alone
Number of subjects: 121
Study 19705245 — intervention group
Group type: EXPERIMENTAL
Intervention: 8 mg dexamethasone
Number of subjects: 36
Study 19705245 — intervention group
Group type: EXPERIMENTAL
Intervention: 16 mg dexamethasone
Number of subjects: 36
Study 17576774 — intervention group
Group type: EXPERIMENTAL
Intervention: Culturally targeted materials
Number of subjects: 500
Study 17576774 — intervention group
Group type: COMPARATOR
Intervention: Standard care materials
Number of subjects: 500
Study 15514373 — intervention group
Group type: EXPERIMENTAL
Intervention: LV5FU2 (Leucovorin 200 mg/m2 + Fluorouracil 400 mg/m2 bolus + Fluorouracil 600 mg/m2 continuous infusion)
Number of subjects: 134
Study 15514373 — intervention group
Group type: EXPERIMENTAL
Intervention: LV5FU2 plus cisplatin (50 mg/m2)
Number of subjects: 134
Study 15514373 — intervention group
Group type: EXPERIMENTAL
Intervention: LV5FU2 plus irinotecan (180 mg/m2)
Number of subjects: 134
Study 11694773 — intervention group
Group type: EXPERIMENTAL
Intervention: Concurrent schedule of short-infusion IFO at total dose of 7.5-9 g/m² over 5 days plus iv bolus EPI at 90-120 mg/m²/cycle, repeated every 3 weeks (group A)
Number of subjects: 44
Study 11694773 — intervention group
Group type: COMPARATOR
Intervention: Sequential schedule of dose-intense, continuous infusion IFO at a total dose of 14-18 g/m² for 2 cycles followed by bimonthly EPI at 120-160 mg/m²/cycle (group B)
Number of subjects: 44
Study 9745107 — intervention group
Group type: EXPERIMENTAL
Intervention: Oat milk
Number of subjects: 24
Study 9745107 — intervention group
Group type: EXPERIMENTAL
Intervention: Soya milk
Number of subjects: 24
Study 9745107 — intervention group
Group type: COMPARATOR
Intervention: Cow's milk
Number of subjects: 24
Study 9745107 — intervention group
Group type: EXPERIMENTAL
Intervention: Oat milk, soya milk, cow's milk (combined)
Number of subjects: 24
Study 7880993 — intervention group
Group type: EXPERIMENTAL
Intervention: fentanyl/alpha‐stat
Number of subjects: 32
Study 7880993 — intervention group
Group type: COMPARATOR
Intervention: fentanyl/pH‐stat
Number of subjects: 32
Study 7880993 — intervention group
Group type: EXPERIMENTAL
Intervention: sufentanil/alpha‐stat
Number of subjects: 32
Study 7880993 — intervention group
Group type: COMPARATOR
Intervention: sufentanil/pH‐stat
Number of subjects: 32
Study 1979083 — intervention group
Group type: EXPERIMENTAL
Intervention: LongoVital (LV)
Number of subjects: 31
Study 762958 — intervention group
Group type: EXPERIMENTAL
Intervention: High potassium cardioplegic solution (20 mEq. per liter)
Number of subjects: 50
Study 762958 — intervention group
Group type: COMPARATOR
Intervention: Low potassium cardioplegic solution (5 mEq. per liter)
Number of subjects: 50
Study 31118371 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 mg repaglinide per day (1 mg each time before meals) for 8 weeks
Number of subjects: 234
Study 31118371 — intervention group
Group type: COMPARATOR
Intervention: ABCC8 rs1801261 allele frequency in T2DM patients
Number of subjects: 234
Study 27593087 — intervention group
Group type: EXPERIMENTAL
Intervention: Digital Audio Recording (DAR) and Question Prompt List (QPL)
Number of subjects: 4349
Study 27593087 — intervention group
Group type: EXPERIMENTAL
Intervention: Digital Audio Recording (DAR) only
Number of subjects: 4349
Study 27593087 — intervention group
Group type: COMPARATOR
Intervention: Standard care (Control)
Number of subjects: 4349
Study 25881022 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 years of continued Specialized Early Intervention (SEI)
Number of subjects: 212
Study 25881022 — intervention group
Group type: COMPARATOR
Intervention: Regular care in the community
Number of subjects: 212
Study 23410792 — intervention group
Group type: EXPERIMENTAL
Intervention: Doripenem
Number of subjects: 0
Study 23410792 — intervention group
Group type: COMPARATOR
Intervention: Comparator agents
Number of subjects: 0
Study 20674225 — intervention group
Group type: EXPERIMENTAL
Intervention: Amplified stethoscope (Littman 3100)
Number of subjects: 32
Study 20674225 — intervention group
Group type: COMPARATOR
Intervention: Traditional stethoscope (Littman cardiology III)
Number of subjects: 32
Study 18936867 — intervention group
Group type: EXPERIMENTAL
Intervention: Macroplastique(R) (MPQ) Implantation System (MIS)
Number of subjects: 45
Study 17041001 — intervention group
Group type: EXPERIMENTAL
Intervention: Risedronate 2.5 mg/day (group R)
Number of subjects: 38
Study 17041001 — intervention group
Group type: EXPERIMENTAL
Intervention: Alfacalcidol 0.5 mug/day (group A)
Number of subjects: 38
Study 17041001 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of risedronate and alfacalcidol (group R+A)
Number of subjects: 38
Study 17041001 — intervention group
Group type: COMPARATOR
Intervention: Risedronate (group R)
Number of subjects: 38
Study 17041001 — intervention group
Group type: COMPARATOR
Intervention: Alfacalcidol (group A)
Number of subjects: 38
Study 17041001 — intervention group
Group type: COMPARATOR
Intervention: All groups
Number of subjects: 38
Study 17051709 — intervention group
Group type: EXPERIMENTAL
Intervention: Local hyperthermia using balloon-type electrodes in combination with standard chemo- and radiotherapy
Number of subjects: 0
Study 17051709 — intervention group
Group type: COMPARATOR
Intervention: Standard chemo- and radiotherapy
Number of subjects: 0
Study 11555746 — intervention group
Group type: EXPERIMENTAL
Intervention: Vestibular rehabilitation combined with cognitive behavioral therapy
Number of subjects: 19
Study 11555746 — intervention group
Group type: COMPARATOR
Intervention: Waiting-list control
Number of subjects: 19
Study 9783297 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitremer with primer (20 preps)
Number of subjects: 32
Study 9783297 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitremer without primer (19 preps)
Number of subjects: 32
Study 9783297 — intervention group
Group type: COMPARATOR
Intervention: Z100 with Scotchbond Multi‐Purpose (18 preps)
Number of subjects: 32
Study 7929519 — intervention group
Group type: EXPERIMENTAL
Intervention: Synthetic donor site dressing
Number of subjects: 38
Study 7929519 — intervention group
Group type: COMPARATOR
Intervention: Impregnated gauze dressing
Number of subjects: 38
Study 3309480 — intervention group
Group type: EXPERIMENTAL
Intervention: Blood cardioplegia
Number of subjects: 103
Study 3309480 — intervention group
Group type: COMPARATOR
Intervention: Crystalloid cardioplegia
Number of subjects: 103
Study 3309480 — intervention group
Group type: COMPARATOR
Intervention: Diltiazem crystalloid cardioplegia
Number of subjects: 103
Study 31985112 — intervention group
Group type: EXPERIMENTAL
Intervention: Melatonin 5 mg nightly for five nights
Number of subjects: 120
Study 31985112 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120
Study 29858041 — intervention group
Group type: EXPERIMENTAL
Intervention: Decision support application
Number of subjects: 67
Study 29858041 — intervention group
Group type: COMPARATOR
Intervention: Regular procedure without the App
Number of subjects: 67
Study 26554378 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with OLP (case group)
Number of subjects: 30
Study 26554378 — intervention group
Group type: COMPARATOR
Intervention: Healthy subjects (control group)
Number of subjects: 30
Study 26554378 — intervention group
Group type: EXPERIMENTAL
Intervention: Comparison of secretor status between OLP patients and controls
Number of subjects: 30
Study 25555358 — intervention group
Group type: EXPERIMENTAL
Intervention: Decision support tool with auditory and visual prompts
Number of subjects: 65
Study 25555358 — intervention group
Group type: COMPARATOR
Intervention: Memory alone (control group)
Number of subjects: 65
Study 23583817 — intervention group
Group type: EXPERIMENTAL
Intervention: PVRV administered intramuscularly (1 ml)
Number of subjects: 60
Study 23583817 — intervention group
Group type: EXPERIMENTAL
Intervention: PVRV administered intradermally (0.1 ml)
Number of subjects: 60
Study 23583817 — intervention group
Group type: COMPARATOR
Intervention: Commercially available PVRV (Verorab) administered intramuscularly
Number of subjects: 60
Study 23583817 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups (including control)
Number of subjects: 60
Study 21958773 — intervention group
Group type: EXPERIMENTAL
Intervention: Statin therapy targeting LDL levels less than 100 mg/dL
Number of subjects: 0
Study 21958773 — intervention group
Group type: EXPERIMENTAL
Intervention: Statin therapy targeting LDL levels less than 70 mg/dL
Number of subjects: 0
Study 21958773 — intervention group
Group type: EXPERIMENTAL
Intervention: Consistent statin use throughout the trial period
Number of subjects: 0
Study 21958773 — intervention group
Group type: COMPARATOR
Intervention: Patients with LDL levels >100 mg/dL
Number of subjects: 0
Study 18559235 — intervention group
Group type: EXPERIMENTAL
Intervention: Qinzhu Liangxue Decoction (QZLXD)
Number of subjects: 58
Study 18559235 — intervention group
Group type: COMPARATOR
Intervention: Ampeptide
Number of subjects: 58
Study 16385088 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin at 150 to 200 mg per day
Number of subjects: 871
Study 16385088 — intervention group
Group type: COMPARATOR
Intervention: No treatment (control group)
Number of subjects: 871
Study 14666440 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonidine 5 microg x kg(‐1) (group HD)
Number of subjects: 45
Study 14666440 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonidine 2 microg x kg(‐1) (group ND)
Number of subjects: 45
Study 14666440 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam 0.1 mg x kg(‐1) (group midazolam)
Number of subjects: 45
Study 10971792 — intervention group
Group type: EXPERIMENTAL
Intervention: orlistat 120 mg three times daily
Number of subjects: 376
Study 8782006 — intervention group
Group type: EXPERIMENTAL
Intervention: Tauroursodeoxycholic acid (10 mg kg‐1)
Number of subjects: 0
Study 8782006 — intervention group
Group type: EXPERIMENTAL
Intervention: Ursodeoxycholic acid (10 mg kg‐1)
Number of subjects: 0
Study 8782006 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 1616093 — intervention group
Group type: EXPERIMENTAL
Intervention: Isosorbide dinitrate spray (30 s before induction)
Number of subjects: 60
Study 1616093 — intervention group
Group type: EXPERIMENTAL
Intervention: Isosorbide dinitrate spray (90 s before induction)
Number of subjects: 60
Study 1616093 — intervention group
Group type: COMPARATOR
Intervention: Placebo buccal spray (90 s before induction)
Number of subjects: 60
Study 1616093 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 60
Study 6379142 — intervention group
Group type: EXPERIMENTAL
Intervention: High sugar diet
Number of subjects: 20
Study 6379142 — intervention group
Group type: COMPARATOR
Intervention: Low sugar diet
Number of subjects: 20
Study 31209448 — intervention group
Group type: EXPERIMENTAL
Intervention: Carisolv
Number of subjects: 32
Study 31209448 — intervention group
Group type: EXPERIMENTAL
Intervention: Papacârie
Number of subjects: 32
Study 31209448 — intervention group
Group type: COMPARATOR
Intervention: Mechanical excavation (hand excavator)
Number of subjects: 32
Study 29280726 — intervention group
Group type: EXPERIMENTAL
Intervention: Strategy training
Number of subjects: 30
Study 29280726 — intervention group
Group type: COMPARATOR
Intervention: Attention control
Number of subjects: 30
Study 27430256 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin 850 mg BID for 12 months
Number of subjects: 150
Study 27430256 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 12 months
Number of subjects: 150
Study 25033153 — intervention group
Group type: EXPERIMENTAL
Intervention: Scattered-site public housing
Number of subjects: 453
Study 25033153 — intervention group
Group type: COMPARATOR
Intervention: Clustered public housing
Number of subjects: 453
Study 25033153 — intervention group
Group type: EXPERIMENTAL
Intervention: More network members who smoked
Number of subjects: 453
Study 22156234 — intervention group
Group type: EXPERIMENTAL
Intervention: Parental component intervention (n = 1226)
Number of subjects: 2232
Study 22156234 — intervention group
Group type: COMPARATOR
Intervention: No parental component intervention (n = 1006)
Number of subjects: 2232
Study 19154859 — intervention group
Group type: EXPERIMENTAL
Intervention: Spiritual mantram intervention
Number of subjects: 71
Study 19154859 — intervention group
Group type: COMPARATOR
Intervention: Attention-matched control group
Number of subjects: 71
Study 19154859 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 71
Study 17135183 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceftriaxone administered by 24 h continuous infusion
Number of subjects: 57
Study 17135183 — intervention group
Group type: COMPARATOR
Intervention: Ceftriaxone administered by once‐daily intermittent bolus dosing
Number of subjects: 57
Study 16266472 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalapril (10 mg per day)
Number of subjects: 105
Study 16266472 — intervention group
Group type: COMPARATOR
Intervention: Indapamide (2.5 mg per day)
Number of subjects: 105
Study 12412696 — intervention group
Group type: EXPERIMENTAL
Intervention: Talcage (TT)
Number of subjects: 108
Study 12412696 — intervention group
Group type: COMPARATOR
Intervention: Pleural Drainage (PD)
Number of subjects: 108
Study 10374624 — intervention group
Group type: EXPERIMENTAL
Intervention: Clenbuterol 60 micrograms Bid for more than 3 months
Number of subjects: 71
Study 10374624 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 71
Study 7889440 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetylsalicylic acid (ASA) at doses of 80 to 1300 mg (Part 1)
Number of subjects: 50
Study 7889440 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic dose of ASA (325 mg) (Part 2)
Number of subjects: 50
Study 7889440 — intervention group
Group type: COMPARATOR
Intervention: ASA nonresponders (Part 1)
Number of subjects: 50
Study 7889440 — intervention group
Group type: COMPARATOR
Intervention: ASA nonresponders (Part 2)
Number of subjects: 50
Study 2228924 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylphenidate treatment during double-blind trials
Number of subjects: 9
Study 2228924 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylphenidate treatment
Number of subjects: 9
Study 2228924 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study 657455 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral sodium (100 mEq) with 200ml of 5% dextrose in water intravenously
Number of subjects: 8
Study 657455 — intervention group
Group type: COMPARATOR
Intervention: Intravenous sodium (100 mEq) with placebo capsules orally
Number of subjects: 8
Study 657455 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral sodium (50 mEq) in patients with primary adrenocortical insufficiency
Number of subjects: 8
Study 657455 — intervention group
Group type: COMPARATOR
Intervention: Intravenous sodium (50 mEq) in patients with primary adrenocortical insufficiency
Number of subjects: 8
Study 30298281 — intervention group
Group type: EXPERIMENTAL
Intervention: Sustained elevation of postoperative serum CA19-9 levels (Group E, n = 159)
Number of subjects: 539
Study 30298281 — intervention group
Group type: COMPARATOR
Intervention: No elevation of postoperative serum CA19-9 levels (Group N, n = 380)
Number of subjects: 539
Study 30298281 — intervention group
Group type: EXPERIMENTAL
Intervention: Sustained elevation of postoperative serum CA19-9 levels (Group E)
Number of subjects: 539
Study 30298281 — intervention group
Group type: COMPARATOR
Intervention: No elevation of postoperative serum CA19-9 levels (Group N)
Number of subjects: 539
Study 30298281 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative CA19-9 elevation
Number of subjects: 539